Immix Biopharma, Inc. (IMMX)

2.1300 -0.1700 (-7.39%) At close: 04:00PM EDT

Immix Biopharma, Inc.

11400 West Olympic Boulevard
Suite 200
Los Angeles, CA 90064
United States
310 651 8041
https://www.immixbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 14

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.	Co-Founder, CEO & Chairman	637.5k	N/A	1973
Mr. Gabriel Morris B.A.	CFO & Director	637.5k	N/A	1987
Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc	Co-Founder	N/A	N/A	N/A
Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.	Scientific Co-Founder	N/A	N/A	1947
Mr. Ben H. Lyon J.D.	Executive VP & General Counsel	N/A	N/A	N/A
Dr. Graham Ross FFPM, M.D.	Chief Medical Officer & Head of Clinical Development	N/A	N/A	1960
Mr. Nandan Oza B.S.	Head of Chemistry, Manufacturing & Control	N/A	N/A	1962
Dr. David Marks	Chief Medical Officer of Cell Therapy	N/A	N/A	N/A
Mr. Gerhard Bauer	Head of Cell Thearpy Manufacturing	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Corporate governance

Immix Biopharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.